PUBLIC COMPANY
saveSling Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Sling banks $123M for an experimental thyroid eye disease pillA confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.biopharma_dive · 16d ago
- Sling catches $123M series C for thyroid eye disease pillSling Therapeutics is advancing the first late-stage oral drug for thyroid eye disease that, if approved, could compete against Amgen and Viridian Therapeutics.biospace · 16d ago
- Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye diseaseInvestors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. S…endpoints · 16d ago
- Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trialSling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.fiercebiotech · 17d ago
comments(0)
5-min edit window · permanent after that